Evidence map›Paper›PMID 41405720›Full record

ArticleJournal of cancer research and clinical oncology2025

Quality of care before and after initial certification at a German certified hereditary breast and ovarian cancer center.

Niklas Amann, Manuel Hörner, Henrik Spannring, Lena Brückner, Julia Gocke, Carolin Müller, Cornelia Boesl, Simon Bader, Felix Heindl, Carolin C Hack and 3 more

Abstract read
In one paragraph

Article in Journal of cancer research and clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Breast cancer prevention in patients with gBRCA-mutated ovarian cancer.Journal of cancer research and clinical oncology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Niklas AmannDepartment of Gynecology and Obstetrics, Universitätsklinikum Erlangen, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Universitätsstraße 21/23, 91054, Erlangen, Germany. niklas.amann@uk-erlangen.de.ORCID http://orcid.org/0009-0005-5280-2800
Manuel HörnerDepartment of Gynecology and Obstetrics, Universitätsklinikum Erlangen, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Universitätsstraße 21/23, 91054, Erlangen, Germany.
Henrik SpannringDepartment of Gynecology and Obstetrics, Universitätsklinikum Erlangen, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Universitätsstraße 21/23, 91054, Erlangen, Germany.
Lena BrücknerDepartment of Gynecology and Obstetrics, Universitätsklinikum Erlangen, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Universitätsstraße 21/23, 91054, Erlangen, Germany.
Julia GockeDepartment of Gynecology and Obstetrics, Universitätsklinikum Erlangen, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Universitätsstraße 21/23, 91054, Erlangen, Germany.
Carolin MüllerDepartment of Gynecology and Obstetrics, Universitätsklinikum Erlangen, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Universitätsstraße 21/23, 91054, Erlangen, Germany.
Cornelia BoeslDepartment of Gynecology and Obstetrics, Universitätsklinikum Erlangen, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Universitätsstraße 21/23, 91054, Erlangen, Germany.
Simon BaderDepartment of Gynecology and Obstetrics and CCC Munich LMU, LMU University Hospital, Munich, Germany.
Felix HeindlDepartment of Gynecology and Obstetrics, Universitätsklinikum Erlangen, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Universitätsstraße 21/23, 91054, Erlangen, Germany.
Carolin C HackDepartment of Gynecology and Obstetrics, Universitätsklinikum Erlangen, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Universitätsstraße 21/23, 91054, Erlangen, Germany.
Peter A FaschingDepartment of Gynecology and Obstetrics, Universitätsklinikum Erlangen, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Universitätsstraße 21/23, 91054, Erlangen, Germany.
Matthias W BeckmannDepartment of Gynecology and Obstetrics, Universitätsklinikum Erlangen, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Universitätsstraße 21/23, 91054, Erlangen, Germany.
Annika KrückelDepartment of Gynecology and Obstetrics, Universitätsklinikum Erlangen, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Universitätsstraße 21/23, 91054, Erlangen, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeGenetic mutations contribute to around 10% of breast and 25% of ovarian cancers, with one third of patients having a familial cancer history. The German Consortium for Familial Breast and Ovarian Cancer was founded in 1996 to improve care for these patients. Certification of cancer centers, introduced in 2004, has been linked to improved survival rates and ensures adherence to evidence-based standards. This study investigates changes in care structures and quality before and after the initial certification of the HBOC center at the University Hospital Erlangen, certified from 2021 on.

methodsThis retrospective study analyzed patient data from January 2018 to December 2023 at the certified Hereditary Breast and Ovarian Cancer center at the University Hospital Erlangen. Eligibility for genetic counseling and germline testing followed the German Cancer Society criteria. After informed consent, Next Generation Sequencing was performed, and variants were classified according to Human Genome Variation Society and American College of Medical Genetics and Genomics standards. Medical histories and genetic results were recorded in electronic case report forms.

resultsFrom 2018 to 2023, a total of 2694 genetic tests were performed, increasing from 962 pre-certification to 1732 post-certification (+ 180%). Testing among affected female patients doubled. Genetic testing in breast cancer patients increased from 551 to 1,04, while testing for ovarian carcinoma rose from 117 to 159. Variants of uncertain significance were identified in approximately 9% of cases during both periods. Pathogenic findings were observed in 14.3% of cases pre-certification (with 9.2% involving BRCA1/2 mutations) and 11.5% post-certification (6.4% BRCA1/2 mutations). Enrollment in the intensified surveillance program (IBCS) increased by 182.5%, accompanied by a rise in recommendations for risk-reducing surgeries.

conclusionCertification of medical institutions ensures high-quality, evidence-based patient care and increases the utilization of preventive and counseling services, particularly for Hereditary Breast and Ovarian Cancer. Further studies are needed to confirm the long-term impact and necessity of certification.

Indexed as

Breast NeoplasmsCancer Care FacilitiesCertificationHereditary Breast and Ovarian Cancer SyndromeOvarian NeoplasmsQuality of Health CareAdultAgedFemaleGenetic TestingGermanyHumansMiddle AgedRetrospective StudiesBRCABreast cancerCertificationGenetic testingHBOCOvarian cancer

Identifiers

PMID41405720
PMCPMC12711623

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.